Search

Objectives. To investigate the influence of 6 months of treatment with an oral contraceptive (OC) containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate on plasma viscosity (PV) in young women with polycystic ovary syndrome (PCOS). Design. Patients with PCOS were assessed for PV before and after 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate. PV was determined by a viscometer Type 53610/I SCHOTT-Instruments, Mainz at 37°C. Settings. Subjects were recruited from the Department of Obstetrics and Gynaecology, Division of Reproductive Endocrinology at the University Hospital of Patras, Greece. Patients. The study included 66 young women with PCOS. Main outcome measures. PV. Results. In PCOS women as a whole, PV at baseline was 1.249 ± 0.049 mm2/s ( n == 66). After 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate, PV was increased to 1.268 ± 0.065 mm2/s ( p == 0.038). The difference between PV before and after 6 months of treatment with an OC containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate (Δviscosity) was 0.01864 ± 0.071452 mm2/s. ΔViscosity was related to Δfibrinogen ( r == 0.270, p == 0.046), to Δhematocrit ( r == 0.514, p == 0.09) and to Δtriglycerides ( r == 0.292, p == 0.021). Conclusion. Young women with PCOS presented an increased PV under OC treatment with 35 μg ethinyl estradiol and 2 mg cyproterone acetate. [ABSTRACT FROM AUTHOR]

Objective. To investigate the plasma viscosity in young women with polycystic ovary syndrome (PCOS). Design. Patients with PCOS and healthy controls were assessed for plasma viscosity. The acquired data were tested for association with hyperandrogenemia, obesity and insulin resistance (IR) in patients with PCOS. Plasma viscosity was determined by a viscometer Type 53610/I SCHOTT-Instruments, Mainz at 37°C. Patients. The study included 96 young women with PCOS and 72 healthy controls. Main outcome measures. Plasma viscosity and IR. Results. Plasma viscosity was 1.243 ± 0.67 mm2/s in the control group and 1.252 ± 0.82 in women with PCOS (p = 0.416). Using multiple regression analysis, total protein (B = 0.348, p = 0.005), area under curve for insulin (B = 0.320, p = 0.011) and BMI (B = 0.315, p = 0.013) were proven to be significantly correlated to plasma viscosity. Plasma viscosity was significantly increased in women with PCOS with IR compared to matched for age and BMI PCOS women without IR (1.300 ± 0.055 vs. 1.231 ± 0.049 mm2/s) (p = 0.004). Conclusion. Young women with PCOS presented a plasma viscosity that was increased by obesity and IR. Therefore, clinical management of young overweight women with PCOS with IR should always include a serious reduction in body weight and the use of oral contraceptive treatment with cautious. [ABSTRACT FROM AUTHOR]